Remove 2014 Remove Competition Remove Doctors Remove Healthcare Provider
article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs. Biogen’s activity in multiple sclerosis.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

16,17 However, care must be taken to ensure that chemicals from biomass are not produced in competition with food production and do not have a negative impact on the environment or natural habitats. Chem Commun 2014, 50, 9650‒9652. Hoffmann-La Roche Ltd based in Basel, Switzerland. Org Process Res Dev 2022, 26, 9, 2685–2693.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Liron Fendell

Cadensee

Until back in 2014, I met the team at Schneider Children's Medical Center of Israel. And I was lucky enough the team at Schneider's and Clalit Healthcare , who is the owner of Schneider Hospital. They want it to be backed by doctors. That it is was developed by doctors and backed by doctors.

Retail 52
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. These actions allegedly led to the extension of Novartis’ patents. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.